Adstiladrin Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Adstiladrin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increased approval of gene therapy products, a rise in the number of patients diagnosed with urothelial carcinoma, increasing demand for immunotherapy, a rise in the number of clinical trials, and growing healthcare expenditures.

Market growth during the forecast period can be attributed to the increasing incidence of non-muscle-invasive bladder cancer, a rising number of BCG-unresponsive cases, increasing investment in cancer research, rising global healthcare expenditure, and a growing preference for gene therapy. Major trends in the forecast period include technological advancements, personalized medicine, the adoption of biomarkers, artificial intelligence, and advances in liquid biopsy technology.

The rising incidence of bladder cancer is expected to significantly drive the growth of the adstiladrin market. Bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC), is increasing due to factors such as smoking, an aging population, environmental toxins, and improved diagnostic methods. Adstiladrin, which is specifically designed for high-risk NMIBC patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy, offers an effective treatment option that helps avoid the need for radical surgery. For example, in January 2024, the American Cancer Society reported a slight increase in bladder cancer cases, highlighting the growing need for treatments like adstiladrin.

The rising healthcare expenditure is expected to fuel the growth of the adstiladrin market. Healthcare spending is increasing globally due to aging populations, the prevalence of chronic diseases, advancements in medical technology, and higher drug costs. This growth in healthcare expenditure enables greater investment in innovative therapies like Adstiladrin, which improves treatment access for high-risk bladder cancer patients. For example, in May 2023, the UK’s healthcare expenditure rose to approximately $348 billion, with non-government healthcare spending growing by 9.5%. Such trends support the expansion of markets for advanced treatments like adstiladrin.

A key trend in the adstiladrin market is the development of innovative therapies, such as adenovirus vector-based gene therapies, which aim to improve treatment outcomes. Adstiladrin itself is an innovative treatment, utilizing a gene therapy approach to target bladder wall cells and enhance the body's natural defenses against cancer. In December 2022, Adstiladrin received FDA approval for treating high-risk NMIBC with carcinoma in situ (CIS) that is unresponsive to BCG. This approval followed successful Phase 3 trials, demonstrating the therapy's efficacy in providing sustained cancer control. Such innovations are expected to drive further adoption of Adstiladrin in the treatment of bladder cancer.

Key player operating in the adstiladrin market is Ferring Pharmaceuticals Inc.

North America was the largest region in the adstiladrin market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in adstiladrin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adstiladrin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adstiladrin is a gene therapy medication designed to treat high-risk non-muscle-invasive bladder cancer (NMIBC) that does not respond to Bacillus Calmette-Guérin (BCG) therapy. It contains nadofaragene firadenovec, a non-replicating adenoviral vector that delivers the interferon alfa-2b gene directly to bladder cells. This delivery stimulates the local production of interferon alfa-2b, a protein with antitumor properties, enhancing the immune system's ability to target and destroy cancer cells.

The main indications for adstiladrin include high-risk non-muscle-invasive bladder cancer (NMIBC) and other bladder cancer variants. NMIBC is a type of bladder cancer where the tumor is confined to the inner lining of the bladder and has a high risk of recurrence or progression. Adstiladrin is distributed through various channels, including hospitals and clinics, retail pharmacies, and specialty pharmacies, and is used by both adult and geriatric patients.

The adstiladrin market research report is one of a series of new reports that provides adstiladrin market statistics, including adstiladrin industry global market size, regional shares, competitors with a adstiladrin market share, detailed adstiladrin market segments, market trends and opportunities, and any further data you may need to thrive in the adstiladrin industry. This adstiladrin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adstiladrin market consists of sales of gene therapy medications, adenoviral vectors, immune checkpoint inhibitors and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.